(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 April 2007 (05.04.2007)

PCT

(10) International Publication Number
WO 2007/036745 A3

(51) International Patent Classification:
A61K 47/02 (2006.01) *A61K 9/00* (2006.01)
A61K 47/12 (2006.01) *A61K 39/395* (2006.01)
A61K 47/26 (2006.01) *C07K 16/24* (2006.01)

(21) International Application Number:
PCT/GB2006/003650

(22) International Filing Date:
29 September 2006 (29.09.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0519923.7 30 September 2005 (30.09.2005) GB
60/721,974 30 September 2005 (30.09.2005) US

(71) Applicant *(for all designated States except US)*: **CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge CB1 6GH (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FISH, Brendan, Cormick** [GB/GB]; Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge CB1 6GH (GB). **LANGSTONE, Jeanette, Elizabeth** [GB/GB]; Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge CB1 6GH (GB). **BANNISTER, Karen** [GB/GB]; Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge CB1 6GH (GB). **HOPE, Claire, Louise** [GB/GB]; Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge CB1 6GH (GB).

(74) Agent: **GIBSON, Mark**; Barker Brettell, St John's Innovation Centre, Cowley Road, Cambridge CB4 0WS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
2 August 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INTERLEUKIN-13 ANTIBODY COMPOSITION

(57) Abstract: The invention relates to a pharmaceutical composition comprising an interleukin-13 antibody, more particularly a monoclonal interleukin-13 antibody, especially a human interleukin-13 monoclonal antibody, to a process for purifying said antibody and to the use of said composition in treating interleukin-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, chronic obstructive pulmonary disease, scleroderma, inflammatory bowel disease and Hodgkin's lymphoma, particularly asthma.

WO 2007/036745 A3